Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells

Journal for ImmunoTherapy of Cancer

Charlie Garnett-Benson¹  Susanna F Greer¹  Ercan Cacan¹  Anita Kumari¹ 

[1] Department of Biology, Center for Inflammation, Infection and Immunity, Georgia State University, 161 Jesse Hill Jr. Dr, Atlanta, GA, USA

关键词: Effector co-stimulation;    Epigenetic;    CTLs;    Immunogenic modulation;    External beam radiation;   

Others  :  814925
DOI  :  10.1186/2051-1426-1-17

 received in 2013-04-23, accepted in 2013-09-12,  发布年份 2013

【 摘 要 】

Background

Sub-lethal doses of radiation can alter the phenotype of target tissue by modulating gene expression and making tumor cells more susceptible to T-cell-mediated immune attack. We have previously shown that sub-lethal tumor cell irradiation enhances killing of colorectal carcinoma cells by tumor-specific cytotoxic T cells by unknown mechanisms. Recent data from our lab indicates that irradiation of tumor cells results in the upregulation of OX40L and 41BBL, and that T cells incubated with irradiated tumor cells displayed improved CTL survival, activation and effector activity. The objective of this current study was to determine the mechanism of enhanced OX40L and 41BBL expression in human colorectal tumor cells.

Methods

Two colorectal carcinoma cell lines, HCT116 and SW620, were examined for changes in the expression of 41BBL and OX40L in response to inhibition of histone deacetylases (using TSA) and DNA methyltransferases (using 5-Aza-2′-deoxycytidine) to evaluate if epigenetic mechanisms of gene expression can modulate these genes. Tumor cells were treated with radiation, TSA, or 5-Aza-dC, and subsequently evaluated for changes in gene expression using RT-qPCR and flow cytometry. Moreover, we assessed levels of histone acetylation at the 41BBL promoter using chromatin immunoprecipitation assays in irradiated HCT116 cells.

Results

Our data indicate that expression of 41BBL and OX40L can indeed be epigenetically regulated, as inhibition of histone deacetylases and of DNA methyltransferases results in increased OX40L and 41BBL mRNA and protein expression. Treatment of tumor cells with TSA enhanced the expression of these genes more than treatment with 5-Aza-dC, and co-incubation of T cells with TSA-treated tumor cells enhanced T-cell survival and activation, similar to radiation. Furthermore, chromatin immunoprecipitation experiments revealed significantly increased histone H3 acetylation of 41BBL promoters specifically following irradiation.

Conclusions

Full understanding of specific mechanisms of immunogenic modulation (altered expression of immune relevant genes) of irradiated tumor cells will be required to determine how to best utilize radiation as a tool to enhance cancer immunotherapy approaches. Overall, our results suggest that radiation can be used to make human tumors more immunogenic through epigenetic modulation of genes stimulatory to effector T-cells.

【 授权许可】

   
2013 Kumari et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW: Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003, 170:6338-6347.
• [2]Friedman EJ: Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002, 8:1765-1780.
• [3]Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11:728-734.
• [4]Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW: Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64:7985-7994.
• [5]Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW: Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 2006, 12:1897-1905.
• [6]Ifeadi V, Garnett-Benson C: Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS One 2012, 7:e31762.
• [7]Brzoska K, Szumiel I: Signalling loops and linear pathways: NF-kappaB activation in response to genotoxic stress. Mutagenesis 2009, 24:1-8.
• [8]Makinde AY, John-Aryankalayil M, Palayoor ST, Cerna D, Coleman CN: Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy. Mol Cancer Res 2013, 11:5-12.
• [9]Janssens S, Tschopp J: Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ 2006, 13:773-784.
• [10]Li N, Karin M: Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci USA 1998, 95:13012-13017.
• [11]Schreck R, Albermann K, Baeuerle PA: Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992, 17:221-237.
• [12]Amundson SA, Do KT, Fornace AJ Jr: Induction of stress genes by low doses of gamma rays. Radiat Res 1999, 152:225-231.
• [13]Gasser S, Raulet DH: The DNA damage response arouses the immune system. Cancer Res 2006, 66:3959-3962.
• [14]Sreekumar A, Nyati MK, Varambally S, Barrette TR, Ghosh D, Lawrence TS, Chinnaiyan AM: Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res 2001, 61:7585-7593.
• [15]Bubenik J: Tumour MHC class I downregulation and immunotherapy (Review). Oncol Rep 2003, 10:2005-2008.
• [16]French LE, Tschopp J: Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol 2002, 12:51-55.
• [17]Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, et al.: Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1994, 1:357-364.
• [18]Zamai L, Rana R, Mazzotti G, Centurione L, Di Pietro R, Vitale M: Lymphocyte binding to K562 cells: effect of target cell irradiation and correlation with ICAM-1 and LFA-3 expression. Eur J Histochem 1994, 38(Suppl 1):53-60.
• [19]Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H: Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther 2004, 11:665-680.
• [20]Modrak DE, Gold DV, Goldenberg DM, Blumenthal RD: Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy. Tumour Biol 2003, 24:32-39.
• [21]Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, et al.: Signaling through OX40 enhances antitumor immunity. Semin Oncol 2010, 37:524-532.
• [22]Kroczek RA, Mages HW, Hutloff A: Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 2004, 16:321-327.
• [23]Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
• [24]Kober J, Leitner J, Klauser C, Woitek R, Majdic O, Stockl J, Herndler-Brandstetter D, Grubeck-Loebenstein B, Reipert BM, Pickl WF, et al.: The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 2008, 38:2678-2688.
• [25]Curtsinger JM, Lins DC, Mescher MF: Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003, 197:1141-1151.
• [26]Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z: Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 2006, 211:81-92.
• [27]al-Shamkhani A, Birkeland ML, Puklavec M, Brown MH, James W, Barclay AN: OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol 1996, 26:1695-1699.
• [28]Garber K: Beyond ipilimumab: new approaches target the immunological synapse. J Natl Cancer Inst 2011, 103:1079-1082.
• [29]Waller EC, McKinney N, Hicks R, Carmichael AJ, Sissons JG, Wills MR: Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells. Blood 2007, 110:4360-4366.
• [30]Habib-Agahi M, Jaberipour M, Searle PF: 4-1BBL costimulation retrieves CD28 expression in activated T cells. Cell Immunol 2009, 256:39-46.
• [31]Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP: Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011, 6:e19499.
• [32]Pan PY, Zang Y, Weber K, Meseck ML, Chen SH: OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther 2002, 6:528-536.
• [33]Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3:682-685.
• [34]Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, Reilly RT: OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol 2006, 176:974-983.
• [35]Vire B, de Walque S, Restouin A, Olive D, Van Lint C, Collette Y: Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. PLoS One 2009, 4:e7085.
• [36]Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A: HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011, 117:2910-2917.
• [37]Han Y, Wang Y, Xu HT, Yang LH, Wei Q, Liu Y, Zhang Y, Zhao Y, Dai SD, Miao Y, et al.: X-radiation induces non-small-cell lung cancer apoptosis by upregulation of Axin expression. Int J Radiat Oncol Biol Phys 2009, 75:518-526.
• [38]Gal-Yam EN, Saito Y, Egger G, Jones PA: Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 2008, 59:267-280.
• [39]Cheng YW, Pincas H, Bacolod MD, Schemmann G, Giardina SF, Huang J, Barral S, Idrees K, Khan SA, Zeng Z, et al.: CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res 2008, 14:6005-6013.
• [40]Kouzarides T: Chromatin modifications and their function. Cell 2007, 128:693-705.
• [41]Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu Rev Biochem 2001, 70:81-120.
• [42]Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D: Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 2001, 104:119-130.
• [43]Eberharter A, Becker PB: Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002, 3:224-229.
• [44]Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000, 97:10014-10019.
• [45]Dion MF, Altschuler SJ, Wu LF, Rando OJ: Genomic characterization reveals a simple histone H4 acetylation code. Proc Natl Acad Sci USA 2005, 102:5501-5506.
• [46]Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
• [47]Kadosh D, Struhl K: Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters. Cell 1997, 89:365-371.
• [48]Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K: Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138:1019-1031.
• [49]Glozak MA, Seto E: Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
• [50]Barneda-Zahonero B, Parra M: Histone deacetylases and cancer. Mol Oncol 2012, 6:579-589.
• [51]Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202.
• [52]Wang H, Gao X, Yang JJ, Liu ZR: Interaction between p68 RNA helicase and Ca2+-calmodulin promotes cell migration and metastasis. Nat Commun 2013, 4:1354.
• [53]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
• [54]Ali MW, Cacan E, Liu Y, Pierce JY, Creasman WT, Murph MM, Govindarajan R, Eblen ST, Greer SF, Hooks SB: Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One 2013, 8:e60185.
• [55]Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995, 87:982-990.
• [56]Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, Cole D, Lam C, Schlom J: Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997, 3:2439-2449.
• [57]Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T: Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res 2002, 62:961-966.
• [58]Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA: Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res 2009, 15:3406-3415.
• [59]Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997, 57:808-811.
• [60]Maeda T, Towatari M, Kosugi H, Saito H: Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000, 96:3847-3856.
• [61]Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP: Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 1999, 162:3273-3279.
• [62]Prado-Garcia H, Romero-Garcia S, Morales-Fuentes J, Aguilar-Cazares D, Lopez-Gonzalez JS: Activation-induced cell death of memory CD8+ T cells from pleural effusion of lung cancer patients is mediated by the type II Fas-induced apoptotic pathway. Cancer Immunol Immunother 2012, 61:1065-1080.
• [63]Chiou SH, Sheu BC, Chang WC, Huang SC, Hong-Nerng H: Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol 2005, 67:35-50.
• [64]Zola H: Markers of cell lineage, differentiation and activation. J Biol Regul Homeost Agents 2000, 14:218-219.
• [65]Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G: Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008, 15:3-12.
• [66]Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR: Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013, 133(3):624-636. 10.1002/ijc.28070
• [67]Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
• [68]Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, et al.: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556.
• [69]Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K, Kano Y, Ishii H: Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J Cell Physiol 2005, 203:387-397.
• [70]Earel JK Jr, VanOosten RL, Griffith TS: Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res 2006, 66:499-507.
• [71]Fornace AJ Jr, Amundson SA, Do KT, Meltzer P, Trent J, Bittner M: Stress-gene induction by low-dose gamma irradiation. Mil Med 2002, 167:13-15.
• [72]Woloschak GE, Paunesku T: Mechanisms of radiation-induced gene responses. Stem Cells 1997, 15(Suppl 2):15-25.
• [73]Chen M, Quintans J, Fuks Z, Thompson C, Kufe DW, Weichselbaum RR: Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. Cancer Res 1995, 55:991-994.
• [74]Ropero S, Esteller M: The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007, 1:19-25.
• [75]Sharma NL, Groselj B, Hamdy FC, Kiltie AE: The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU Int 2013, 111:537-542.
• [76]Redner RL, Wang J, Liu JM: Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999, 94:417-428.
• [77]Saunders N, Dicker A, Popa C, Jones S, Dahler A: Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res 1999, 59:399-404.
• [78]Yoshida M, Horinouchi S: Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann N Y Acad Sci 1999, 886:23-36.
• [79]Kosugi H, Towatari M, Hatano S, Kitamura K, Kiyoi H, Kinoshita T, Tanimoto M, Murate T, Kawashima K, Saito H, Naoe T: Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 1999, 13:1316-1324.
• [80]Rajgolikar G, Chan KK, Wang HC: Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res Treat 1998, 51:29-38.
• [81]Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD: Science gone translational: the OX40 agonist story. Immunol Rev 2011, 244:218-231.